Navigation Links
Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor

BOSTON, Nov. 27, 2012 /PRNewswire/ -- Rhythm announced today that the company has raised an additional $8 million to complete a $33 million Series B financing. The additional $8 million comes from new investor, Pfizer Venture Investments, the venture capital arm of Pfizer. Pfizer joins existing investors MPM Capital, New Enterprise Associates, Third Rock Ventures, and Ipsen, which all participated in a first closing of the Series B financing earlier this year.

Rhythm will use the proceeds to further develop its small-peptide therapeutics for metabolic diseases. RM-131 is a ghrelin agonist currently in Phase 2 clinical trials for diabetic gastroparesis and GI functional disorders. RM-493 is a melanocortin 4 receptor (MC4R) agonist that is completing Phase 1 clinical trials for the treatment of obesity and diabetes. This additional financing brings the total capital raised by Rhythm to $73 million.

"We are excited to have the support of Pfizer Ventures as we advance both metabolic programs through Phase 2 trials," said Bart Henderson, Co-Founder and President of Rhythm. "The Pfizer team has deep commercial and development experience that we intend to leverage as we expand the clinical trial program for these two important new therapeutics."

"The obesity and diabetes epidemics represent one of the largest medical challenges confronting society today," said Dr. Barbara Dalton, Vice President Venture Capital, Pfizer Venture Investments. "Rhythm's metabolic programs are compelling because of the initial proof-of-concept data from ongoing clinical programs, along with the fact that peptide therapeutics have delivered high success rates in clinical development. We are pleased to help Rhythm capitalize on its opportunities."

About Pfizer Venture Investments
Pfizer Venture Investments (PVI), the venture capital arm of Pfizer Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of the Worldwide Business Development division, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline and shape the future of our industry. For more information, please visit 

About Rhythm (
Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm is developing the ghrelin peptide agonist, RM-131, for the treatment of diabetic gastroparesis and other GI functional disorders, and the MC4R peptide agonist, RM-493, for obesity and diabetes. Rhythm investors include MPM Capital, New Enterprise Associates, Third Rock Ventures, Ipsen, and Pfizer Venture Investments. The company is based in Boston, Massachusetts.

Bart Henderson
(857) 264-4281

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Rhythm Names Lex Van der Ploeg Chief Scientific Officer
2. Rap music powers rhythmic action of medical sensor
3. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
4. Rhythmic firing of nerve cells involved in bodys movements
5. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
6. UV Flu Technologies Expands Its International Footprint
7. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
8. Ansell Limited Expands Korean Presence
9. Premier Research Expands Salt Lake City and Phoenix Testing Facilities Adding 50% Capacity
10. Groundbreaking National Program to Reverse Obesity Expands to 50 Locations
11. Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team
Post Your Comments:
(Date:12/1/2015)... OXFORD, England , December 1, 2015 ... Touch is a touch activated lancet that features Owen ... Vancouver , booth 1403, Unistik® Touch is a ... Zone Technology®. --> Owen Mumford, a leading ... its range of medical devices, available initially in the ...
(Date:12/1/2015)... SEATTLE , Dec. 1, 2015 Today ... headquarters in Seattle,s South Lake ... northwest corner of Mercer Street and Westlake Avenue North, ... to the Allen Institute for Brain Science and the ... Allen , philanthropist and founder of the Allen Institute. ...
(Date:12/1/2015)... -- Researchers at the Broad Institute of MIT and ... MIT have engineered changes to the revolutionary CRISPR-Cas9 genome ... errors. The refined technique addresses one of the major ... Science , Feng Zhang and his ... amino acids that make up the Cas9 enzyme from ...
(Date:12/1/2015)... Dec. 1, 2015  Twist Bioscience, a company focused on ... , Ph.D., has been selected as one of Foreign ... fast-tracking the building blocks of life . Each year, ... whose contributions and work have changed lives and are shaping ... "It is an honor to be recognized among these incredible ...
Breaking Biology Technology:
(Date:12/1/2015)... JOSE, Calif. , Dec. 1, 2015 ... of human interface solutions, today announced a new agreement ... enable OEMs with real-world test and development environments that ... Labs solutions. The partnership reduces the complexity of FIDO ... and software permits Synaptics and OEMs to verify FIDO ...
(Date:11/30/2015)... DEERFIELD BEACH, Fla. , Nov. 30, 2015 ... selected as a finalist in this year,s Fierce Innovation ... publisher of FierceHealthIT , ... BIOCLAIM was recognized as a finalist in the ... --> ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Capacitive Fingerprint Sensors - Technology and ... --> --> ... market, especially in smartphones. The fingerprint sensor vendor Idex ... fingerprint sensor units in mobile devices and of the ...
Breaking Biology News(10 mins):